CompletedNot Applicable

Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence

Italy237 participantsStarted 2022-06-03

Plain-language summary

This is a retrospective study of single-center cohorts that involves patients with HCC who underwent liver transplantation between January 2016 and 2021, who received livers preserved with Hypothermic Oxygenated Perfusion (HOPE) or Static Cold Storage (SCS) with a minum follow up of 12 months.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Recipients aged 18 years or older with previous diagnosis of HCC, undergone Liver Transplantation at the Transplant Center of the IRCCS AOUBO between January 2016 and 2021 * Patients who have given informed consent to participate in the study Exclusion Criteria: * none

What they're measuring

Risk of HCC tumour recurrence

Timeframe: From liver transplant to twelve months after LT

Trial details

NCT IDNCT06720675

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-01-08

View on ClinicalTrials.gov More Liver Carcinoma trials